Before starting a statin, which statement is correct regarding monitoring for muscle-related adverse effects?

Before starting a statin, which statement is correct regarding monitoring for muscle-related adverse effects?

• A. Do not start a statin if the baseline CK is over 5x ULN
• B. Start a statin if baseline CK is high
• C. CK is irrelevant
• D. Only stop if symptoms occur

Answer: (A)

Creatine kinase (CK) is a marker of muscle injury, and statins carry a risk of muscle-related adverse effects, including myopathy and, rarely, rhabdomyolysis. If a patient’s CK is markedly elevated before starting a statin—specifically more than five times the upper limit of normal—that finding suggests an underlying muscle condition or another cause of muscle injury. In that scenario, starting a statin could worsen muscle damage, so the appropriate course is to withhold the statin and investigate the cause of the CK elevation before proceeding with lipid-lowering therapy. If CK is not elevated at baseline, you can initiate a statin with routine monitoring for muscle symptoms, and if symptoms develop during treatment, CK should be checked and management adjusted accordingly.

Creatine kinase (CK) is a marker of muscle injury, and statins carry a risk of muscle-related adverse effects, including myopathy and, rarely, rhabdomyolysis. If a patient’s CK is markedly elevated before starting a statin—specifically more than five times the upper limit of normal—that finding suggests an underlying muscle condition or another cause of muscle injury. In that scenario, starting a statin could worsen muscle damage, so the appropriate course is to withhold the statin and investigate the cause of the CK elevation before proceeding with lipid-lowering therapy. If CK is not elevated at baseline, you can initiate a statin with routine monitoring for muscle symptoms, and if symptoms develop during treatment, CK should be checked and management adjusted accordingly.